Natural panax notoginseng-derived nanovesicles trigger multiple cell death mechanisms and reprogram chemokine signaling to impede oral squamous cell carcinoma progression

Read full text
Authors: Xiaohang Chen, Lin Meifang, Xuzheng Zhan, Genggeng Zheng, Shuoqi Lin, Liyu Huang, C Zhang, Yuxiang Yan, Hengyi Li, Zhaoyu Zhang, Xing Wang, Y. Charles Lu
+1 more Dali Zheng
Cited by: 2
References: 59

Abstract

Oral squamous cell carcinoma (OSCC) remains one of the most aggressive malignancies of the oral epithelium, with limited therapeutic options effectively targeting both tumor growth and metastasis. Plant-derived nanovesicles have emerged as natural, biocompatible nanomedicines with potential applications in cancer therapy. Here, we systematically screened nanovesicles from ten medicinal plants and identified Panax notoginseng-derived nanovesicles (PnNVs) as the most potent inhibitors of OSCC. PnNVs exhibited favorable safety profiles and intrinsic tumor-homing ability, selectively accumulating in orthotopic tongue tumors. In vivo, they markedly suppressed primary tumor growth and lymphatic metastasis. Mechanistically, PnNVs disrupted redox homeostasis by inhibiting the p38-MAPK/NRF2 signaling pathway, thereby inducing ferroptosis, autophagy, and PANoptosis. In addition, PnNVs impaired cancer cell migration by modulating chemokine-associated signaling pathways critical for tumor dissemination. Multi-omic analyses further revealed synergistic contributions of RNA cargos and metabolite components to their multi-target anticancer efficacy. Collectively, our findings establish PnNVs as a natural, multifunctional therapeutic candidate with dual anti-proliferative and anti-metastatic activity, providing a promising preclinical strategy for OSCC treatment.

Fields of Study & Subjects

Ferroptosis and cancer prognosis Ginseng Biological Effects and Applications Autophagy in Disease and Therapy

Publication details

Journal / source
Journal of Nanobiotechnology
Publisher
Springer Science and Business Media LLC
Volume
24
Issue
1
Publication date
6 March 2026
Language
EN